Surreal illustration of a pregnant woman surrounded by swirling arteries and a glowing placenta, symbolizing the interplay between maternal cardiovascular health and fetal development.

Decoding Hypertension in Pregnancy: Can Arterial Stiffness and Placental Growth Predict Outcomes?

Soraya Malik monogram
Soraya Malik in Health & Wellness October 2026 • 4 min read.

"New research explores how arterial stiffness and placental growth factors may predict adverse pregnancy outcomes in women with chronic hypertension, potentially improving risk stratification and future interventions."


Chronic hypertension during pregnancy poses significant risks, often leading to adverse outcomes such as preeclampsia, fetal growth restriction, and preterm birth. Identifying women at high risk early in pregnancy is crucial for timely intervention and improved maternal and fetal health. Traditional methods of risk assessment often fall short, prompting researchers to explore novel biomarkers and diagnostic tools.

A recent study published in the American Journal of Obstetrics & Gynecology investigated the potential of arterial stiffness and placental growth factor (PlGF) as independent predictors of adverse pregnancy outcomes in women with chronic hypertension. The study aimed to determine whether these factors could help identify women at higher risk for early placental disease and other complications.

The prospective cohort study, conducted between 2012 and 2017, recruited 503 women with a diagnosis of hypertension made before pregnancy or before 20 weeks gestation, and/or a history of preeclampsia. Researchers measured pulse wave velocity (PWV), a measure of arterial stiffness, and PlGF, a protein essential for placental development, throughout the pregnancy.

AI Search Multiple angles on this topic

The Scope of Hypertensive Disorders in Pregnancy

Hypertensive disorders of pregnancy (HDP) represent a significant global health concern, affecting a notable proportion of pregnancies worldwide and contributing substantially to maternal and fetal complications. These conditions remain among the leading causes of maternal morbidity and mortality, with effects that can extend well beyond the delivery period. Accurate early identification of at-risk pregnancies is crucial for improving outcomes, yet current screening methods face considerable challenges.

Current Screening Limitations and the Promise of Arterial Stiffness

Hypertensive disorders of pregnancy are a leading cause of maternal morbidity and mortality worldwide, yet accurate early clinical screening methods for the development of these disorders are lacking. Arterial stiffness (AS) has emerged as an important hemodynamic indicator of vascular health that shows promising results for predicting HDP onset. Past systematic reviews have highlighted the potential of AS measurements, though standardizing these approaches for routine clinical use remains an ongoing challenge.

Foundational Understanding of Arterial Stiffness in Pregnancy

In the pathological development of gestational hypertension or pre-eclampsia, arterial stiffness or reduced arterial compliance occurs alongside diffuse vasoconstriction and increased peripheral vascular resistance arising from endothelial dysfunction. In the general population, arterial stiffness and central blood pressure are established markers of vascular health and prognostic indicators for cardiovascular disease. In pregnancy, arterial stiffness has gained particular attention in women with hypertensive disorders, representing a convergence of cardiovascular research and obstetric care.

How Arterial Stiffness and Placental Growth Impact Pregnancy Outcomes

Surreal illustration of a pregnant woman surrounded by swirling arteries and a glowing placenta, symbolizing the interplay between maternal cardiovascular health and fetal development.

The study's results indicated that women who developed early placental disease, defined as requiring delivery before 34 weeks due to preeclampsia, exhibited significantly elevated PWV and lower PlGF levels throughout gestation. These findings suggest that increased arterial stiffness and impaired placental development, as reflected by reduced PlGF, are associated with adverse pregnancy outcomes in women with chronic hypertension.

Specifically, the research highlighted several key findings:

  • Elevated PWV: Women with early placental disease had higher pulse wave velocity, indicating stiffer arteries, which can impair blood flow to the placenta.
  • Reduced PlGF: Lower levels of placental growth factor suggested compromised placental development and function.
  • Prior Pregnancy Impact: In women with a history of complicated pregnancies, early pregnancy PWV was not as elevated, but PlGF levels were still significantly lower, indicating that prior pregnancy history can modify these biomarkers.
  • Predictive Power: Combining PWV and PlGF measurements in early pregnancy demonstrated a modest sensitivity (77%) for predicting early placental disease, with a positive predictive value of 24%.
AI Search Multiple angles on this topic

Emerging Evidence and Research Directions

Research into arterial stiffness as a predictive tool for hypertensive disorders of pregnancy continues to evolve, with investigators exploring various measurement techniques and their clinical applications. The field is moving toward understanding how vascular changes detected early in pregnancy might inform intervention strategies. While promising, many findings remain in the research phase, and translating these discoveries into routine clinical practice requires further validation across diverse populations.

Challenges and Limitations in Current Approaches

Despite the promise of arterial stiffness measurements, significant challenges remain in establishing them as reliable predictive tools. Questions persist about the optimal timing of measurements, the most appropriate techniques for different populations, and how to integrate these assessments into existing prenatal care workflows. Additionally, the heterogeneity of hypertensive disorders themselves complicates efforts to develop universal screening protocols that work across all patient subgroups.

Arterial Stiffness Across Hypertensive Pregnancy Subtypes

Women who develop hypertensive disorders of pregnancy have higher brachial and aortic augmentation index (AIx) compared with normotensive controls. Notably, aortic AIx appears highest in those who deliver a small-for-gestational-age neonate, suggesting this measure may help identify not only hypertensive risk but also fetal growth complications. These findings indicate that different forms of hypertensive disorders in pregnancy may present with distinct vascular profiles that could inform more personalized clinical management.

These results emphasize the importance of assessing arterial stiffness and placental growth in hypertensive women during early pregnancy to identify those at highest risk for complications. The study's findings suggest that these metrics could provide valuable insights into placental function and cardiovascular health, enabling more targeted interventions.

Future Implications and Early Intervention

The study underscores the potential of arterial stiffness and placental growth factor as valuable tools for risk stratification in pregnant women with chronic hypertension. By identifying women at higher risk for early placental disease, healthcare providers can implement targeted interventions, such as intensified monitoring, medication adjustments, and lifestyle modifications, to improve pregnancy outcomes.

AI Search Multiple angles on this topic

Expert Perspectives on Arterial Stiffness in Preeclampsia Prediction

Arterial stiffness is recognized as an important hemodynamic indicator of vascular health that has shown promising results for the early prediction of preeclampsia. Research from multiple groups has demonstrated that arterial stiffness measurements could improve early identification of women at risk for hypertensive disorders of pregnancy. This convergence of evidence from independent research programs suggests that AS measurements may eventually become a valuable adjunct to current screening approaches.

Looking Ahead: Research Priorities and Clinical Translation

The future of arterial stiffness assessment in pregnancy will likely involve standardizing measurement protocols and validating these approaches in larger, more diverse cohorts. Integration with other biomarkers and clinical risk factors may enhance predictive accuracy. As research progresses, there is potential for these tools to become part of routine prenatal screening, though significant work remains to establish their clinical utility and cost-effectiveness in real-world healthcare settings.

Long-Term Implications and System-Wide Considerations

Hypertension in pregnancy contributes substantially to maternal morbidity and mortality, persistent hypertension, and rehospitalization. Hypertensive disorders of pregnancy are also associated with a heightened risk of cardiovascular disease, making timely recognition and modification of associated risk factors crucial in optimizing long-term maternal health. Research has shown that adverse effects of HDP on the fetal cardiovascular system and brain development are likely to persist across the life span, with children born from mothers with preeclampsia having increased risk of obesity, chronic hypertension, and systemic vascular dysfunction.

Patient Experiences and Clinical Implications

Women with a history of gestational hypertensive disease show an increased prevalence of prehypertension and elevated arterial stiffness in subsequent pregnancies. Research has documented that arterial stiffness measures, including wave reflection, are increased during pregnancy among women with pre-eclampsia and gestational hypertension, and these vascular changes may persist after delivery. These findings underscore the importance of longitudinal monitoring for women with a history of hypertensive disorders, both during and after pregnancy.

  • 1.10±0.14 vs 0.99±0.11 MoMsAdjusted carotid-femoral PWV was 1.10±0.14 MoMs in the pre-eclampsia group versus 0.99±0.11 MoMs in the non-pre-eclampsia group.[1]

What PWV and PlGF comparisons suggest-and do not settle

Across the cited comparisons, higher PWV tracks with pre-eclampsia, but that pattern alone does not establish that PWV can distinguish who will later develop it in every risk group.[2] [3]

PlGF thresholds can show strong predictive performance in the reviewed screening evidence, while the authors caution that usefulness depends on whether testing improves outcomes, not just on prediction statistics.[4]

The reported reduction in severe maternal adverse outcomes with revealed PlGF testing is a comparison with usual care; it points to a possible clinical effect, but does not by itself show which part of care produced the difference.[5]

How other pregnancy reports frame vascular and placental signals

A risk-factor cohort found that pulse wave analysis added no predictive information beyond blood pressure and maternal risk profile, a reminder that a vascular signal may not improve an existing assessment in every population.[3]

Other reports describe varied study populations: one included women with multiple pre-eclampsia risk factors, while another compared severe pre-eclampsia, gestational hypertension, chronic hypertension, and normal pregnancy.[3] [6]

A longitudinal normal-pregnancy report excluded participants who developed pre-eclampsia or gestational hypertension, so its comparison group was deliberately distinct from cohorts focused on pregnancy complications.[7]

Mechanistic accounts connect impaired placental blood flow and oxygenation with dysfunctional spiral-artery invasion; other descriptions link placental syndromes to altered circulating angiogenic balance and complications including restricted fetal growth and preterm delivery.[1] [4] [8]

What remains unresolved about these signals

  • Does revealing PlGF results improve outcomes because it changes clinical decisions, and would that effect hold beyond the populations represented in the testing comparison?[4] [5]
  • Can prospective evidence establish whether altered arterial stiffness gradients identify later obstetric complications, as the proposed mechanism suggests?[9]

Terms behind the vascular and placental measures

Pulse wave velocity
PWV[1]
Placental growth factor
PlGF[8]
Spiral arteries
Maternal arteries whose impaired trophoblastic invasion is linked to placental hypoperfusion and hypoxia.[1]
Angiogenic factors
Circulating factors described as imbalanced in a placental-origin systemic syndrome.[4]

Sources

  1. Maternal Arterial Stiffness in Women Who Subsequently Develop Pre-Eclampsia (pmc.ncbi.nlm.nih.gov)
  2. The association between pulse wave velocity and pregnancy-associated diseases: A systematic review and meta-analysis (pmc.ncbi.nlm.nih.gov)
  3. Pulse wave analysis for the prediction of preeclampsia. (pubmed.ncbi.nlm.nih.gov)
  4. Predictive Performance of PlGF (Placental Growth Factor) for Screening Preeclampsia in Asymptomatic Women: A Systematic Review and Meta-Analysis. (pubmed.ncbi.nlm.nih.gov)
  5. Placental growth factor measurements in the assessment of women with suspected Preeclampsia: A stratified analysis of the PARROT trial (pmc.ncbi.nlm.nih.gov)
  6. Aortic stiffness in normal and hypertensive pregnancy. (pubmed.ncbi.nlm.nih.gov)
  7. Pulse Wave Analysis in Normal Pregnancy: A Prospective Longitudinal Study (pmc.ncbi.nlm.nih.gov)
  8. Clinical utility of sFlt-1 and PlGF in screening, prediction, diagnosis and monitoring of pre-eclampsia and fetal growth restriction. (obgyn.onlinelibrary.wiley.com)
  9. Center-To-Periphery Arterial Stiffness Gradient Is Attenuated and/or Reversed in Pregnancy-Associated Hypertension (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What is the significance of arterial stiffness, measured by Pulse Wave Velocity (PWV), in predicting adverse pregnancy outcomes for women with chronic hypertension?

Arterial stiffness, measured by Pulse Wave Velocity (PWV), plays a crucial role in predicting adverse pregnancy outcomes in women with chronic hypertension. The research indicates that women who developed early placental disease had higher PWV, signifying stiffer arteries. This stiffness can impede blood flow to the placenta, thereby potentially causing complications such as preeclampsia, fetal growth restriction, and preterm birth. Elevated PWV in early pregnancy is therefore indicative of increased risk, providing a valuable biomarker for risk stratification and the potential for early intervention.

2

How does Placental Growth Factor (PlGF) relate to pregnancy outcomes, and what does its reduced level signify in the context of chronic hypertension?

Placental Growth Factor (PlGF) is a critical protein for placental development and function. Reduced levels of PlGF during pregnancy, particularly in women with chronic hypertension, are strongly associated with compromised placental development and function. The study showed that women who experienced adverse pregnancy outcomes had lower PlGF levels. This reduction suggests that the placenta may not be developing or functioning optimally, which can lead to complications such as preeclampsia and fetal growth restriction. Therefore, assessing PlGF levels can help identify women at higher risk, enabling timely interventions to improve pregnancy outcomes.

3

Can the combined use of PWV and PlGF measurements improve the prediction of early placental disease in women with chronic hypertension? What are the limitations?

The combined use of Pulse Wave Velocity (PWV) and Placental Growth Factor (PlGF) measurements shows promise in predicting early placental disease in women with chronic hypertension. The research found that combining both metrics in early pregnancy had a modest sensitivity (77%) for predicting early placental disease. However, the positive predictive value was 24%, indicating that while the test can identify many at-risk women, a significant number of women identified as high-risk may not develop complications. This highlights a limitation where further refinement of the predictive model, potentially including additional biomarkers or clinical factors, may be needed to increase accuracy and reduce false positives.

4

How does a prior history of complicated pregnancies impact the relationship between PWV and PlGF in women with chronic hypertension?

A history of complicated pregnancies can modify the relationship between Pulse Wave Velocity (PWV) and Placental Growth Factor (PlGF) in women with chronic hypertension. The research noted that, in women with a history of complicated pregnancies, early pregnancy PWV was not as elevated as in women without such a history. However, PlGF levels were still significantly lower, suggesting that prior pregnancy complications can influence the biomarkers. This indicates that while arterial stiffness might not be as pronounced in early pregnancy for these women, compromised placental development, as reflected by reduced PlGF, remains a key indicator of risk. This highlights the importance of considering individual patient history in risk assessment.

5

What interventions can be considered based on findings related to arterial stiffness and PlGF in pregnant women with chronic hypertension?

Based on the findings related to arterial stiffness (PWV) and Placental Growth Factor (PlGF), healthcare providers can implement targeted interventions to improve pregnancy outcomes in women with chronic hypertension. These interventions may include intensified monitoring to closely observe the pregnancy's progress, medication adjustments to better manage the hypertension and reduce the risk of complications, and lifestyle modifications such as dietary changes and increased physical activity. The goal is to mitigate risks associated with adverse outcomes, potentially reducing preeclampsia, fetal growth restriction, and preterm birth, thereby improving both maternal and fetal health.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.